Announcements Trials
Browse Landscape

Phase

Phase 4 2Phase NA 1Phase 1/2 1

Status

Active not recruiting 2Recruiting 1Completed 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Sarcoma 5Breast 4CNS 3Thoracic 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Breast Neoplasms 3Breast Cancer Metastatic 1

Interventions

Paclitaxel 161Fulvestrant 155Trastuzumab 152pembrolizumab 144Letrozole 136Carboplatin 118pertuzumab 104Cyclophosphamide 102Capecitabine 102Specimen Handling 101Anastrozole 90palbociclib 85abemaciclib 81Magnetic Resonance Spectroscopy 81exemestane 76Docetaxel 76Tamoxifen 75ribociclib 73trastuzumab deruxtecan 69Radiotherapy 61Biopsy 59Surveys and Questionnaires 56Gemcitabine 52130-nm albumin-bound paclitaxel 52sacituzumab govitecan 50olaparib 50Standard of Care 49Blood Specimen Collection 49Taxes 47Doxorubicin 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Zoledronic Acid × Breast × 1 year × Clear all
NCT06374459 2026-04-20

Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis

Washington University School of Medicine

Phase 1/2 Recruiting
152 enrolled
Breast

Breast Neoplasms

NCT04549207 2026-04-07

Comparing Continuation or De-escalation of Bone Modifying Agents (BMA) in Patients Treated for Over 2 Years for Bone Metastases From Either Breast or Castration-resistant Prostate Cancer

Ottawa Hospital Research Institute

Phase 4 Active not recruiting
240 enrolled
Breast

Breast Neoplasms

NCT03664687 2026-02-09

REaCT-ZOL

Ottawa Hospital Research Institute

Phase 4 Completed
211 enrolled
Breast

Breast Neoplasms

NCT06876636 2025-07-29

Zoledronic Acid Combined With EC-T for Triple-Negative Breast Cancer

Xijing Hospital

Phase NA Active not recruiting
99 enrolled
Breast

Breast Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡